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Glucocorticoids are steroid hormones that play critical and complex roles in the regulation of triglyceride (TG)
homeostasis. Depending on physiological states, glucocorticoids can modulate both TG synthesis and hydrolysis.
More intriguingly, glucocorticoids can concurrently affect these two processes in adipocytes. The metabolic effects
of glucocorticoids are conferred by intracellular glucocorticoid receptors (GR). GR is a transcription factor that, upon
binding to glucocorticoids, regulates the transcriptional rate of specific genes. These GR primary target genes
further initiate the physiological and pathological responses of glucocorticoids. In this article, we overview
glucocorticoid-regulated genes, especially those potential GR primary target genes, involved in glucocorticoid-
regulated TG metabolism. We also discuss transcriptional regulators that could act with GR to participate in these
processes. This knowledge is not only important for the fundamental understanding of steroid hormone actions,
but also are essential for future therapeutic interventions against metabolic diseases associated with aberrant
glucocorticoid signaling, such as insulin resistance, dyslipidemia, central obesity and hepatic steatosis.
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The balance of lipogenesis and lipolysis is vital for main-
taining triglyceride (TG) homeostasis in mammals. Several
endocrine systems play important roles in these processes.
Glucocorticoids are steroid hormones that carry critical
and complex actions in TG metabolism. During fasting
and starvation, increased levels of glucocorticoids in circu-
lation stimulates lipolysis in adipocytes, and TG is hydro-
lyzed to fatty acids (FA) and glycerol. Free FA (FFA) are
mobilized to skeletal muscle and liver to be oxidized and
used as energy, whereas glycerol becomes the substrate
for hepatic gluconeogenesis. Such metabolic adaptation is
critical for the survival of mammals during fasting and
starvation. During the fed state, glucocorticoids participate
in lipid metabolism for several physiological purposes.
Animals starved for a period of 36–56 hr and then fed
with high glucose diet showed an increase of hepatic de
novo lipogenesis (DNL) [1]. Intriguingly, these effects are* Correspondence: walwang@berkeley.edu
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reproduction in any medium, provided the orreduced upon adrenalectomy and restored with gluco-
corticoid replacement. Thus, glucocorticoids are required
for feed efficiency [1-4]. Notably, patients with Cushing’s
syndrome, which is characterized by elevated circulating
cortisol levels, have fat accumulation in certain depots,
such as the central abdomen, the supraclavicular region
the face, and the dorsocervical region, the pathognomonic
“buffalo’s hump”. However, fat storage is decreased in sub-
cutaneous depots of the extremities [5,6]. These observa-
tions highlight that glucocorticoids likely affects both
lipogenesis and lipolysis, though depending on different
fat depots. Although there is increased fat mass overall,
Cushing’s syndrome could be accounted for as a result of
fat redistribution. In fact, using stable isotope labeling
technique, it is confirmed that white adipose tissues
(WAT) of mice treated with dexamethasone (DEX, a syn-
thetic glucocorticoid) for 4 days have an increased TG
synthesis and lipolysis concurrently [7]. Why do glucocor-
ticoids concurrently increase TG synthesis and lipolysis in
a futile cycle? By increasing both the synthesis and lipoly-
sis of TG, glucocorticoids could have turned up the gain
of additional hormonal signals that would inhibit TG syn-
thesis or lipolysis alone.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
1-acylglycerol-3-phosphate 
(lysophosphatidic  acid) 
1,2-diacylglycerol-3-phosphate 











Wang et al. Cell & Bioscience 2012, 2:19 Page 2 of 9
http://www.cellandbioscience.com/content/2/1/19While glucocorticoids are important for the regulation
of lipid homeostasis in different physiological states, ex-
cess and/or chronic glucocorticoid exposure can cause
lipid disorders, such as central obesity, dyslipidemia and
fatty liver [5,8]. Excess/chronic glucocorticoid-induced
insulin resistance could partially result from a primary
disruption of lipid homeostasis. Furthermore, excess/
chronic glucocorticoids increase the circulating FFA
and induce ectopic lipid accumulation in skeletal
muscle and liver, all are associated with insulin resist-
ance [9,10]. In contrast, suppressing glucocorticoid ac-
tion in vivo, such as by inhibiting 11β hydroxysteroid
dehydrogenase type 1 (11β-HSD 1, which converts in-
active glucocorticoids to active ones) or activating 11β-
HSD 2 (which converts active glucocorticoids to inactive
ones), improves lipid profiles and insulin sensitivity
[11-17].
The biological effects of glucocorticoids are mainly
conferred by their cognate intracellular receptor, the
glucocorticoid receptor (GR). Upon binding to ligands,
GR associates with genomic glucocorticoid response ele-
ments (GRE) to modulate the transcription of nearby
genes (called GR primary target genes), which in turn
trigger the biological effects of glucocorticoids. GR can
directly bind to the genomic GRE. Alternatively, GR can
occupy the GRE indirectly through association with
other DNA-binding transcription factors. Such a GRE is
called a tethering GRE [18,19]. Recent studies applying
chromatin immunoprecipitation sequencing (ChIPseq)
have identified genome-wide GR binding regions (GBRs)
in distinct cell types [7,20-22]. In these GBRs, the clas-
sical GRE sequences are highly represented, albeit small
differences exist between them [7,20-22] (Table 1). In
any case, the key to understanding the mechanisms of
glucocorticoid-regulated TG homeostasis is to identify
GR primary target genes modulating lipid metabolism
and, furthermore, to elucidate the mechanisms of
glucocorticoid-regulated transcription of these primary
targets. Here, we overview the current knowledge of
glucocorticoid-regulated genes, including their specific
role in metabolic function of glucocorticoids and the
mechanisms governing their transcriptional regulation in
TG metabolism.Table 1 Consensus GRE sequences identified from
ChIPseq experiments
Cell Type Sequences Reference
A549 human lung epithelial RGNACANNNTGTNCY [22]
3 T3-L1 mouse Adipocyte NNNACWNNNTGTNYY [7]
3 T3-L1 mouse predipocyte RGNACANNNTGTNCY [20]
3 T3-L1 mouse predipocyte RGNACWSNVWGTKCY [21]
R: A or G, Y: C or T, W: A or T, S: G or C, K: G or T, N: any nucleotide.GR-regulated genes in lipogenic action
Acetyl-CoA carboxylase and fatty acid synthase
Glucocorticoids regulate several genes encoding enzymes
in DNL and TG synthesis (Figure 1). Acetyl-CoA
Carboxylase 1 and 2 (ACACA and ACACB) encode
rate-controlling enzymes in the FA synthesis pathway.
Glucocorticoids have been shown to increase the ex-
pression of ACACA and ACACB in vitro and in vivo
[23-25]. The human ACACA and ACACB genes con-




Figure 1 Glucocorticoid-regulated genes in lipogenic pathway.
Red indicates potential GR primary target genes, whereas blue
indicates genes regulated by glucocortiocids with no GBR is
identified in or nearby their genomic regions.
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ACACA and ACACB gene promoters can be activated by
glucocorticoids when they are inserted into a synthetic
reporter gene [26]. The exact location of the GRE in
human ACACA and ACACB gene were not reported. With
chromatin immunoprecipitation sequencing (ChIPseq), GR
binding regions (GBR) in or nearby the mouse Acaca and
Acacb genes in 3 T3-L1 mouse adipocytes were identified
[7]. For the mouse Acaca gene, a single GBR is found in
the intron [7]. For the mouse Acacb gene, one GBR is
identified upstream of the transcription start site (TSS),
whereas multiple GBR are found in intronic regions [7].
The ability of these GBR to mediate glucocorticoid-
induced changes in Acaca and Acacb gene expression has
not yet been examined.
Fatty acid synthase (FASN) encodes another rate-
controlling enzyme in lipogenesis. The regulation of
FASN by glucocorticoids has been reported in many
tissues, including liver, adipose tissues, and lung [27].
A previous study showed that glucocorticoid treatment
increases the activity of a reporter gene that contains
−1592 to +65 (relative to TSS) of human FASN gene [28].
Thus, the GRE(s) that mediate the stimulatory effect of
glucocorticoids on FASN gene lies within this −1592 to
+65 region. Transgenic mice harboring a reporter gene
that contains 2.1 kb rat Fasn gene promoter fused to
chloramphenicol acetyltransferase (CAT) were generated
to study the regulation of the Fasn gene in vivo. DEX
treatment increases the reporter gene in multiple tissues,
including liver, white adiopose tissue (WAT), brown adi-
pose tissue (BAT), and lung [29]. This finding suggests
that the GRE(s) lies within this 2.1-kb region upstream
from TSS in the rat Fasn gene. For the mouse Fasn gene,
ChIPseq identified an intronic GBR located within +3248
to +3463 (relative to TSS) region [7]. The function of this
mouse Fasn GBR has not yet been studied.
A recent report shows that despite the observation of
the induction of ACACA, ACACB and FASN gene ex-
pression by corticosterone in a human Chub-S7 adipo-
cyte cell line, lipogenesis is not increased, but decreased
[24]. It is likely due to increased phosphorylation of
ACACA on serine 79/218 which reduces its activity [24].
However, when insulin is present in cultured medium,
corticosterone enhances insulin-stimulated lipogenesis
in these cells [24]. The positive cross-talk between glu-
cocorticoids and insulin in the regulation of lipogenesis
has long been reported, and some studies suggest that
glucocorticoids’ effect on DNL is dependent on insulin
[30,31]. In primary hepatocytes, glucocorticoids have a
small or no effect on FA synthesis. They either play a
permissive role for insulin to induce FA synthesis or en-
hance the insulin effect on FA synthesis [30-32]. In
agreement with these observations, glucocorticoids and
insulin have been shown to have additive or synergisticeffects on ACACA and ACACB gene expression [26,33].
These two hormones also have additive effects on reporter
genes that harbor ACACA PI and ACACB PI promoter
(approximately 2 kb for each promoter) [26]. A similar
positive cross-talk between glucocorticoids and insulin is
found on FASN gene regulation [27,32], as they additively
activate a reporter gene harboring human FASN gene pro-
moter [32].
Genes encoding enzymes in TG synthesis
Glucocorticoids activate the expression of several genes
encoding enzymes in TG synthesis. GR ChIPseq experi-
ments in 3 T3-L1 adipocytes identified GBR in Scd1, Scd2,
Gpat3, Gpat4, Agpat2 and Lpin1 (Figure 1)[7]. The ex-
pression of these genes is also increased by DEX treatment
in 3 T3-L1 adipocytes and mice WAT [7]. When these
GBR are inserted into a reporter plasmid, GBR of all but
Agpat2 can mediate glucocorticoid response [7]. These
data suggest that all of them are likely GR primary target
genes, though the GRE in these GBR have not been identi-
fied. Additional genes encoding enzymes in TG synthetic
pathways, such as Dgat1 and Dgat2 (Figure 1), have been
shown to be regulated by glucocorticoids [15,34]. How-
ever, it is unclear whether they are GR primary target
genes, as no GBR near their genomic regions is identified
so far. Furthermore, a study identified a GRE located be-
tween −311 and −297 of mouse Lpin1 gene [35]. The loca-
tion of this GRE is different from the 4 GBR identified
from our ChIPseq experiment, which are located between
−1099 and −1320, -1709 and −1937, −27515 and −27845,
and −28575 and −29617 [7]. The latter two GBR conferred
glucocorticoid response in reporter assays. It is likely that
multiple GREs are involved in glucocorticoid-activated
Lpin1 gene transcription.
Notably, the precise purpose of glucocorticoids to in-
duce the transcription of these TG synthesis genes has not
yet been well established. Among these glucocorticoid-
regulated genes discussed above, the positive effects of
glucocorticoids on the activity of Lpin1, which contains
phosphatidate phosphatase (PAP1) activity, [36,37] and
Scd1 and Scd2, which possess stearoyll-CoA desaturase
activity, have been reported [38]. The effects of glucocorti-
coids on the activity of Gpat3, Gpat4 and Agpat2 are un-
known. Dolinsky et al. found that DGAT1 and DGAT2
expression in the liver was increased about 60% and
DGAT activity was increased approximately 20% by DEX
[34]. Similar to their effect on FA synthesis, glucocorti-
coids act with insulin to stimulate TG synthesis. The in-
crease of TG synthesis by glucocorticoids alone in
hepatocytes was reported in some studies [39] but not all
[40]. However, the additive or synergistic effect of gluco-
corticoids and insulin on TG synthesis is observed in most
reports [39,40]. Glucocorticoids and insulin both increase





















Figure 2 Glucocorticoids promote lipolysis in adipocytes.
Glucocorticoids (GC) activate the transcription of Lipe, Mgll, and
Angptl4 gene transcription. Lipe and Mgll encode enzymes in the
lipolytic pathway. Angptl4 is a secreted protein that likely binds to
an unknown receptor to increase cAMP levels in adipocytes, which
in turn activates PKA. PKA phosphorylates Lipe, which increases its
activity and translocation from cytosol to lipid droplet. GC also
increase the expression of Pnpla2 and decrease the expression of
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enhances their enzymatic activities [42]. Glucocorticoids
and insulin also act together to increase the expression of
lipoprotein lipase (LPL), which hydrolyzes extracellular
TG to FFA. These FFA can be taken up by adipoyctes and
enter the lipogenic pathway [43,44]. It has been suggested
that insulin increases the stability of Lpl mRNA and the
activity of Lpl in mouse 3 T3-L1 adipocytes and human
primary pre-adipocytes [45]. Glucocorticoids increase the
Lpl mRNA levels in 3 T3-L1 adipocytes and human pri-
mary pre-adipocytes [45], but the mechanisms underlying
these effects are unknown. ChIPseq experiments identified
a GBR located 14 kb upstream of Lpl TSS in 3 T3-L1 adi-
pocytes [7]. The ability of this GBR to mediate gluco-
corticoid responses has not been investigated. The only
gene in the lipogenic pathway whose expression is inhib-
ited by insulin is Lpin 1 [46]. The metabolic significance
of this effect is not entirely clear. Lpin1 expression is
induced upon fasting, and Lpin1 protein has been shown
to participate in transcriptional regulation of genes
involved in FA oxidation, a critical step in metabolic adap-
tation during fasting [47,48]. This function of Lpin1
appears to be independent of its PAP1 activity.Pde3b. The mechanisms for these events are unknown (dashed line).GR-regulated genes in lipolytic action
Genes encoding enzymes in adipocyte lipolysis
Glucocorticoids have been shown to elevate the expres-
sion of genes encoding all three enzymes in the lipolytic
pathway in adipocytes [7,49]. PNPLA2 (also called ATGL
or desnutrin) encodes an enzyme that hydrolyzes TG to
diacyglycerol (DAG) (Figure 2). LIPE (a.k.a. hormone-
sensitive lipase) encodes an enzyme that hydrolyzes
DAG to monoacylglycerol (MAG), whereas MGLL
(monoacylglycerol lipase) encodes an enzyme that hydro-
lyzes MAG to glycerol (Figure 2). The GBR of mouse Lipe
and Mgll genes are identified by ChIPseq, and these GBR
can mediate glucocorticoid response when inserted into a
synthetic reporter plasmid [7]. Thus, Lipe and Mgll are
likely GR primary target genes. The GBR of PNPLA2 gene
has not been identified. Notably, mouse Pnpla2 gene is
positively regulated by a member of FoxO transcription fac-
tors, FoxO1, in 3T3-L1 adipocytes [50]. Glucocorticoids
have been shown to increase the expression of FoxO1 and/
or FoxO3, another member of the FoxO family, in WAT
and other tissues [51-53]. Therefore, glucocorticoids might
activate Pnpla2 gene transcription indirectly through the
elevation of FoxO1 and FoxO3. However, this model
requires confirmation.
It is important to note that insulin represses the expres-
sion and/or the activity of proteins involved in lipolysis,
such as Pnpla2 [54,55] and Lipe [56,57]. This observation
of insulin effect is in contrast to genes involved in lipogen-
esis discussed above.Phosphodiesterase 3B, cGMP-inhibited (PDE3B)
In addition to lipolytic enzymes, the cAMP signaling path-
way plays a key role in the induction of adipocyte lipolysis.
cAMP activates protein kinase A (PKA) that phosphory-
lates LIPE. This phosphorylation increases LIPE enzymatic
activity and translocates LIPE from cytosol to lipid droplet
(Figure 2) [58]. PKA also phosphorylates PLIN1, which can
lead to the stimulation of lipolysis. The details of this path-
way are discussed in several recent reviews [57,59,60].
Glucocorticoid treatment has been shown to increase
cAMP levels in several cell types. However, unlike in neu-
rons where glucocorticoids rapidly increase intracellular
cAMP levels through a non-genomic mechanism [61], in
adipocytes the induction of cAMP levels requires several
hours of glucocorticoid treatment [25,62]. Thus, the
glucocorticoid-elevated cAMP in adipocytes likely requires
the induction of gene transcription and subsequent protein
synthesis. At least two mechanisms are proposed. One is
the inhibition of the expression of PDE3B (Figure 2) [25];
the other is the induction of angiopoietin-like 4 (ANGPTL4,
a.k.a. fasting-induced adipose factor, FIAF) (Figure 2),
which will be discussed later in this review.
PDE3B encodes a protein that decreases cAMP signaling
pathway by hydrolyzing cAMP to AMP in adipocytes. Insu-
lin inhibits PDE3B activity through both phosphoinositide
3-kinase (PI3K)/Akt dependent and independent [63,64]
pathways to suppress lipolysis. The suppression of the
Pde3b expression by glucocorticoids is found both in vivo
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contribute to increased cAMP levels in adipocytes and
the subsequent induction of lipolysis. However, how
glucocorticoids repress Pde3b gene expression has not
been studied.
Carboxyesterase 1d (Ces1d, a.k.a. Triacylglycerol hydrrolase,
TGH)
Dolinsky et al. examined the effects of DEX on hepatic
TG metabolism [34]. Specifically, they focused on the
process where TG, stored in intracellular droplets, are
lipolyzed prior to re-esterification into a VLDL particle.
They observed no effect of DEX on hepatic VLDL secre-
tion in vivo or in vitro, but did find a 50% decrease in
TG turnover in hepatocytes with DEX treatment. Ces1d
is an enzyme believed to mediate the lipolysis of TG in
the liver. Ces1d mRNA levels were decreased by DEX
treatment, but this repression was not due to an effect
on transactivation, as no difference was seen in nuclear
run-on experiments and the Ces1d promoter did not
confer DEX responsiveness in reporter assays. Instead, it
was found that DEX reduced Ces1d mRNA stability via
a 3′ UTR element. These experiments further demon-
strate the complexity of glucocorticoid action on TG
metabolism.
Angptl4
Recent studies also identify Angptl4 as a GR primary target
gene participating in lipid metabolism in liver and WAT
[65]. The Angptl4 gene encodes a secreted protein that inhi-
bits extraceullular LPL and promotes intracellular lipolysis
in adipocytes [62,66,67]. The combination of these two
effects results in the mobilization of lipids from adipocytes
to plasma. Angptl4 null mice (Angptl4−/−) are protected
from excess glucocorticoid-induced hepatic steatosis and
hyperlipidemia [65]. These lipid disorders are attributed, at
least in part, to the ability of glucocorticoids to redistribute
lipids from adipocytes to hepatocytes. Indeed, ANGPTL4
has been shown to participate in glucocorticoid-induced
adipocyte lipolysis (Figure 2) [62], as DEX-stimulated lipoly-
sis is impaired in WAT of Angptl4−/− mice [62]. Intri-
guingly, purified human ANGPTL4 protein (hANGPTL4)
can directly increase adipocyte lipolysis [62].
Circulating glucocorticoid levels are elevated during
fasting. Treatment with RU486, an antagonist of GR,
decreases 24 hr fasting-induced WAT lipolysis. It high-
lights the important role of glucocorticoids in fasting-
induced WAT lipolysis [62]. Angptl4 gene expression is
highly induced upon fasting, an effect that is attenuated
by RU486 treatment [62]. Therefore, glucocorticoids play
a key role in the elevation of Angptl4 gene expression dur-
ing fasting. The fact that WAT from Angptl4−/− mice has
reduced lipolysis with 24 hr fasting [62] further demon-
strates the importance of the glucocorticoid-Angptl4 axisin fasting-induced lipolysis in WAT. In summary, during
fasting, glucocorticoids activate Angptl4 gene expression,
which in turn promotes lipolysis in adipocytes.
Since Angptl4 is a secreted protein, how does it affect
adipocyte lipolysis? Purified hANGPTL4 increases cAMP
levels in adipocytes (Figure 2) [62]. Both fasting and DEX
treatment for 24 hr increases cAMP levels in WAT, but
this induction is impaired in Angptl4−/− WAT [62]. Thus,
ANGPTL4 promotes lipolysis through activating cAMP
pathway. The receptor of ANGPTL4 in adipocytes; how-
ever, has not been identified. Therefore, the intracellular
signaling events that lead to the increase of cAMP pro-
duction are unclear. To date, ANGPTL4 has been shown
to interact with fibronectin, vitronectin and integrin β1β5
in keratinocytes to activate integrin-mediated signaling
[68,69]. Angptl4 also affects other signaling molecules,
such as RAS/ERK [70] and AMP-activated protein kinase
(AMPK) [71] in endothelial cells and hippocampus, re-
spectively. However, whether Angptl4 employs such
mechanisms in adipocytes has not been examined.
The GRE of rat Angptl4 gene is located in the 3′ un-
translated region, between +6227 and +6441 [65]. DEX
treatment increases DNase I sensitivity and histone H4
hyperacetylation in this region. Notably, this GRE is
highly conserved between rat, mouse and human [65].
In the human Angptl4 gene, another GBR is identified
approximately 8 kb upstream from the TSS [72]. Inter-
estingly, insulin has been shown to decrease the expres-
sion of Angptl4 gene [73]. This response is consistent
with the metabolic effect of insulin, which represses adi-
pocyte lipolysis, and the fact that insulin resistance is
highly associated with hyperlipidemia [74,75].
Hes1
Glucocorticoids repress the transcription of a transcrip-
tional repressor, Hes1 [76]. Overexpression of Hes1
increases the expression of pancreatic lipase (Pnlip) and
pancreatic lipase-related protein (Pnliprp2). In liver,
Pnlip and Pnliprp2 contribute to TG hydrolysis and the
subsequent stimulation of fatty acid oxidation and keto-
genesis [77]. Therefore, glucocorticoid-mediated inhib-
ition of the transcription of Hes1 results in a decreased
expression of Pnlip and Pnliprp2, which in turn elevates
hepatic TG accumulation [76]. It is unclear whether
Hes1 directly regulates the transcription of Pnlip and
Pnliprp2, as Hes1 usually serves as a transcriptional re-
pressor. In contrast, Hes1 appears to be a GR primary
target gene. The GRE of the mouse Hes1 gene is located
between −463 and −414 (relative to TSS) [76]. A re-
porter gene that contains −463 to +46 region of the
Hes1 genomic region is suppressed by DEX, whereas a
reporter that contains −414 to +46 region does not re-
spond to DEX [76]. In addition, a consensus GRE half-
site (TGTTCC) was found between −463 and −414, and
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DNA binding to this half-site. In cells overexpressing
wild type GR, DEX treatment reduces the activity of the
reporter containing −463 to +46 of Hes1 gene [76]. In
cells overexpressing GR mutants with defective DNA
binding ability, DEX can no longer suppress the reporter
gene activity [76]. ChIP experiments further confirm the
recruitment of GR to this −463 to +46 region upon DEX
treatment. HDAC1, a transcriptional corepressor, is also
recruited to this region upon DEX treatment [76]. Pre-
sumably, HDAC1 interacts with GR and is responsible
for the inhibition of Hes1 gene transcription. Thus, Hes1
is likely a GR primary target gene that controls hepatic
TG storage by regulating genes involved in TG hydrolysis
in the liver.
GR-regulated genes involved in bile acid metabolism
Na+−taurocholate transport protein (Ntcp/Slc10A1)
Bile acids (BA) are important to dietary fat digestion.
They also serve as ligands for farnesoid X receptor (Fxr),
which regulates TG metabolism. The role of Fxr in TG
metabolism is discussed in a recent review [78]. In liver-
specific GR knock-down mice, BA content in gallbladder
is decreased [79]. Liver BA uptake is impaired and intes-
tinal fat absorption was defective in these mice as there
was greater fecal loss of TG and FFA. Furthermore,
these mice promote greater thermogenic potential as
shown by increased cAMP signaling in BAT and higher
thermogenic gene expression [79]. These phenotypes are
likely attributed, at least in part, to a lower expression of
the major hepatocyte basolateral BA transporter, Nctp
[79]. Nctp affects dietary fat absorption and brown fat
activation. Although the GRE of Nctp has not been iden-
tified, ChIP shows GR occupancy at the proximal pro-
moter of Nctp gene [79]. In mice harboring a GR
mutant that has a mutated dimerization domain and
altered DNA binding ability (GRdim), glucocorticoids do
not activate Ntcp gene expression [79]. These results
suggest that the ability of GR to bind to the GRE is crit-
ical for the induction of Ntcp by glucocorticoids.
Transcriptional regulators that participate in
glucocorticoid-regulated lipid metabolism
GR regulates the transcription of specific genes by inter-
acting with a wide variety of transcription regulators;
however, only few have been shown to participate in
glucocorticoid-regulated transcription of genes involved
in TG metabolism. Here we discuss two transcriptional
regulators that play a role in glucocorticoid-regulated
TG metabolism.
Med1
Med1, a component of Mediator cofactor complex, has
been shown to associate and coactivate with several nuclearreceptors, including GR [80-82]. Gene expression analysis
in Med1 knockout mouse embryonic fibroblast cells shows
that Med1 is selectively required for the regulation of GR
target genes. Med1 contains two LXXLL motifs that are
involved in the interaction with GR [80]. Overexpression of
Med1 enhances glucocorticoid-activated transcription from
an MMTV promoter-based reporter gene. Mutations of
these LXXLL motifs attenuate but do not eliminate this en-
hancement [80]. Indeed, it has been shown that Med1
could be recruited by GR through another pathway. The
N-terminus of Med1 interacts with a transcriptional coacti-
vator, CCAR1, which in turn associates with other tran-
scription coactivators, CoCoA-NCoA1. NCoA1 can directly
associate with the ligand binding domain of GR. The fact
that depletion of CCAR1 in cells reduces ligand-dependent
recruitment of Med1 to the GR-target gene promoters con-
firm the importance of this mechanism for GR-Med1 inter-
action [83].
Excess DEX-induced hepatic steatosis is reduced in
liver-specific Med1 knockout mice (Med1Δliver). In WT
mice, DEX represses the expression of medium- and
short-chain acyl-CoA dehydrogenases (Mcad and Scad),
which encodes enzymes involved in FA oxidation. In
Med1Δliver mice, the repression of Mcad and Scad by DEX
treatment is reduced [84]. Therefore, an increased expres-
sion of genes involved in FA oxidation reduces TG accu-
mulation induced by DEX in the livers of Med1Δliver mice.
Whether Mcad and/or Scad are GR primary target genes
are unclear. Med1 usually serves as a transcriptional coac-
tivator. However, certain coactivators, such as GRIP1/TIF-
2, can also act as a corepressor [85].
Using small hairpin RNA (shRNA) to reduce the ex-
pression of GR in liver, the expressions of genes involved
in FA oxidation, such as carnitine palmitoyltransferase
1α (Cpt1α) and acetyl-CoA acyltransferase 2 (Acaa2), are
increased [76]. These results suggest that GR negatively
regulates hepatic FA oxidation gene expressions. Consid-
ering that the disruption of hepatic Med1 also causes
elevation of genes involved in FA oxidation, it suggests a
link between GR and Med1 in the aspect of regulating
genes in FA oxidation. To test this model, one should
verify whether any of these GR- or Med1-regulated
genes involved in FA oxidation are GR primary target
genes, and then whether Med1 is recruited to their GRE.
Liver X receptor (LXR)
A recent report shows that glucocorticoid-induced hepatic
steatosis is impaired in liver X receptor β null mice
(Lxrβ−/−) [86]. Lxrβ is not a glucocorticoid-regulated gene.
However, Lxrβ is required for glucocorticoid-induced
GR recruitment to the GRE of phosphoenolpyruvate
carboxykinase (Pepck) gene [86], which encodes a rate-
controlling enzyme in gluconeogenesis. Thus, Lxrβ seems
to act as a coactivator for GR to activate gluconeogenic
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Lxrβ appears to affect glucocorticoid-regulated lipid me-
tabolism by modulating glucose metabolism and insulin
sensitivity. Compared to glucocorticoid-treated WT mice,
glucocorticoid-treated Lxrβ−/− mice are more insulin sen-
sitive [86]. This observation could be an explanation for
decreased glucocorticoid-induced TG accumulation in
Lxrβ−/− mice.
Interestingly, another recent report showed that treating
hepatoma cells with LXR ligands suppresses glucocorticoid-
induced Pepck and glucose-6-phosphatase (G6Pase) gene
expression [87]. Microarray analyses showed that LXR
ligand only affects a subset of glucocorticoid-regulated
genes. Both gel shift and ChIP experiments suggest that
LXRα/RXRα heterodimer competes with GR to bind to
the GRE of rat G6pase gene [87]. In agreement with its
effects on DEX-induced gluconeogenic gene expression,
treating rats with a LXR ligand attenuates DEX-increased
plasma glucose levels [87]. Thus, endogenous unliganded
LXRβ is required for a maximal GR occupancy on the
GRE of gluconeogic genes (as discussed in previous
paragraph), whereas LXR ligands appear to suppress
glucocorticoid-activated gluconeogic gene transcription
by inhibiting the recruitment of GR to the GREs of these
genes.Conclusion
In this manuscript, we review glucocorticoid-regulated
genes participating in the modulation of TG metabolism.
In the last decade, with the development of gene expres-
sion arrays and ChIPseq methodologies, the number of
identified potential GR primary target genes has signifi-
cantly increased. However, it is important to note that
only a handful of identified GR primary target genes
have been shown to mediate glucocorticoid effects on
TG metabolism in vivo. The on-going identification of
such “causative primary response genes” (CPRG) is crit-
ical for further elucidation of mechanisms governing the
metabolic effects of glucocorticoids.
Although GBR are being identified in certain
glucocorticoid-regulated genes involved in TG metab-
olism, more studies are required to verify the role of
these GBR in conferring glucocorticoid responses. It
could pose a challenge, as most GBR identified from
ChIPseq are far away from TSS, whereas only less than
10% of GBR are located within 5 kb upstream of TSS
[7,22,72]. The traditional approach focused on this pro-
moter region to identify the GRE of glucocorticoid-
regulated genes. Although inserting GBR into a synthetic
reporter gene to study their enhancer activity is commonly
used, the context of such reporter plasmids could be very
different from the endogenous genomic structure. More
efforts are required to learn the exact role of long-rangeGBR/GRE in the regulation of specific glucocorticoid-
regulated genes.
It is well established that most chromosomal GRE are
composite elements, in which non-GR transcriptional
regulators act with GR to confer a complete hormonal
response [88,89]. Therefore, transcriptional regulatory
complexes, which include GR, non-GR DNA binding
regulators and non-DNA binding cofactors, assembled
on each GRE are likely to be distinct. This suggests that
certain cofactors may be required only for the transcrip-
tional regulation of a subset of glucocorticoid target
genes. Thus, uncovering the specific molecular features
of each GR-containing regulatory complex shall provide
novel and specific targets for therapeutic development.
The dissection of transcriptional mechanisms could also
elucidate the molecular basis of the cross-talk between
glucocorticoids and insulin, specifically, their synergistic
effects on the expression of lipogenic genes and their an-
tagonistic effects on the expression of lipolytic genes. It
is possible that the cross-talk between these two hor-
mones are specified by the interaction between GR and
specific transcription factors. For example, FoxO1 and
FoxO3 have been shown to play an accessory role in
assisting glucocorticoid response and mediating the re-
pressive effect of insulin in certain genes, such as Pepck
and G6Pase [90,91]. Thus, glucocorticoid-activated genes
containing FoxO binding site nearby the GRE may be
usually suppressed by insulin. Transcription factors that
participate in insulin action and functionally interact
with GR to regulate TG metabolism genes are difficult
to speculate, as most of their GRE(s) have not been iden-
tified. Future studies should address these important
issues.
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